Microdose tirzepatide: the clinical case, and the legal one
"Microdose" tirzepatide means roughly 1 mg per week — below every dose studied in SURMOUNT, the trial programme that established tirzepatide's efficacy (5, 10 and 15 mg). It has a genuine clinical rationale for some patients. It is also the regulatory mechanism that lets 503A pharmacies keep compounding tirzepatide at all, now that enforcement discretion has ended. Both of those things are true at once.
Two true things at once
"Microdosing" is marketed as a gentler, cheaper, smarter way to take a GLP-1. Two things are true about it at once, and honest coverage has to hold both.
It has a real clinical rationale for some patients — people who cannot tolerate full-dose escalation, people maintaining after reaching goal weight, and people for whom cost is the binding constraint. A clinician-directed low dose is a legitimate choice for them.
And it is also a regulatory workaround. A dose that is not "the same, similar, or easily substitutable" for an approved strength is a dose that falls outside the "essentially a copy" prohibition — which is the only reason a 503A pharmacy can still compound these molecules at all. The industry-wide pivot to "personalized" and "microdose" dosing tracks the end of enforcement discretion in 2025 almost exactly. That timing is not a coincidence, and no one selling it will tell you so.
What follows for a patient: ask why your specific dose was chosen, and whether the answer is about your body or about the pharmacy's legal position. Expect a smaller effect than the trial headlines. And be aware that evidence for below-label regimens is thin — they have not been through anything resembling SURMOUNT.
How far below the trial doses it sits
| Period | Dose | Note |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Starting dose. Not intended for weight loss — this is a tolerance-building dose. |
| Weeks 5–8 | 5 mg | First therapeutic dose. |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose. |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose. |
1. The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose that is not intended to produce weight loss. Ask what you will pay at 10 mg, and compare that number.
2. A "microdose" of roughly 1 mg/week sits below every dose studied in SURMOUNT. The trials that established tirzepatide's efficacy used 5, 10 and 15 mg. A 1 mg microdose is not a discounted version of that result; it is a different product with a smaller expected effect and no equivalent trial evidence behind it.
What the evidence actually supports
SURMOUNT-1 studied 5 mg, 10 mg and 15 mg, producing mean weight reductions of 15.0%, 19.5% and 20.9% over 72 weeks. A 1 mg microdose has no equivalent trial behind it, and should be expected to produce a smaller effect. That is not a criticism of microdosing — it is arithmetic. Anyone presenting a microdose programme as a cheaper route to the SURMOUNT headline number is misleading you.
| Trial | Arm | Result | Duration | Comparator | Source |
|---|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide 15 mg | −20.9% | 72 weeks | Placebo −3.1% | NEJM 2022 (Jastreboff et al.) |
| SURMOUNT-1 | Tirzepatide 10 mg | −19.5% | 72 weeks | NEJM 2022 | |
| SURMOUNT-1 | Tirzepatide 5 mg | −15.0% | 72 weeks | NEJM 2022 | |
| SURMOUNT-5 | Tirzepatide (max tolerated) | −20.2% | 72 weeks | vs semaglutide −13.7% | NEJM 2025 (Aronne et al.) |
| STEP 1 | Semaglutide 2.4 mg | −14.9% | 68 weeks | Placebo −2.4% | NEJM 2021 (Wilding et al.) |
| STEP 8 | Semaglutide 2.4 mg | −15.8% | 68 weeks | vs liraglutide 3.0 mg −6.4% | JAMA 2022 (Rubino et al.) |
| SCALE | Liraglutide 3.0 mg | −8.0% | 56 weeks | Placebo −2.6% | NEJM 2015 |
| SELECT | Semaglutide 2.4 mg | 20% MACE reduction | ~40 months | Cardiovascular outcomes | NEJM 2023 |
Five questions to ask before you enrol
- Why was this specific dose chosen for me, clinically?
- Is the dose selected partly to keep the product outside the FDA's 'essentially a copy' rule?
- What is the exact salt form and concentration?
- What will I pay if I escalate to a therapeutic dose?
- What happens to my supply if the pharmacy receives an FDA or manufacturer notice?
Monitoring and laboratory work
A legitimate programme does not simply ship medication. Before starting a GLP-1, a clinician should establish a baseline — typically weight and BMI, blood pressure, and laboratory work including HbA1c or fasting glucose, a lipid panel, and renal and hepatic function. A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 is a contraindication, and a history of pancreatitis, gallbladder disease, severe gastrointestinal disease or diabetic retinopathy changes the risk calculus and should be discussed.
During treatment, tolerance should be reviewed at each dose escalation rather than automatically. Persistent vomiting, severe abdominal pain radiating to the back, or signs of gallbladder disease warrant prompt clinical contact rather than a message to a chat widget.
Questions to ask your clinician
- Given my history, is a GLP-1 appropriate for me at all — and is there a reason it might not be?
- What baseline laboratory work will you order before I start?
- What is the target dose, and how quickly will we escalate to it?
- What side effects should make me call you rather than wait?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at follow-up, or a different one each time?
Questions to ask about the pharmacy
The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.
- Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
- Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
- In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
- What is the exact salt form and concentration? Semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
- Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
- Will you provide a certificate of analysis?
- Has the pharmacy received any FDA warning letter or state board action?
A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.
What happens when you stop
This is the question the marketing rarely addresses, and it belongs in any honest discussion of cost. In the published extension data, a substantial proportion of lost weight returns after discontinuation — the STEP 1 extension found participants regained roughly two-thirds of the weight they had lost within a year of stopping.
The practical implication is financial as well as clinical. If maintaining the result requires continuing the medication, then the number that matters is not the monthly price but the indefinite monthly price. A programme that is $186 a month is $2,232 a year, and potentially the same again the year after. Anyone comparing providers on a first-month promotion is optimising the wrong variable.
Storage and handling
Compounded GLP-1 preparations are generally refrigerated, and specific storage requirements vary by pharmacy and formulation — this is one reason a provider that will not tell you which pharmacy compounds your medication is withholding something you need. Ask for the beyond-use date, which for a compounded preparation is not the same as a manufacturer's expiry date and is typically much shorter. Never use a preparation that has changed colour, become cloudy, or contains particulates.
How to verify any of this yourself
You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.
- Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
- Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
- Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
- Ask what the highest dose costs. By email or chat, so you have it in writing.
- Ask about early cancellation before you commit to a plan longer than a month.
- Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.
If a provider will not answer questions 4 or 5 in writing, that is itself information.
Who is actually who: the entities in this transaction
The single biggest source of confusion in telehealth medicine is that people assume one company is doing all of it. Usually four or five separate entities are involved, with different regulators and different duties to you.
| Entity | What it is | Regulated by | What it is NOT |
|---|---|---|---|
| Telehealth company | The website you sign up on. Arranges the consultation, handles billing and logistics. | State corporate practice rules; FTC for advertising | Not a pharmacy. Does not make your medicine. |
| Prescribing clinician | The licensed physician, NP or PA who evaluates you and writes the prescription. | Their state medical or nursing board | Not employed by the pharmacy. Must exercise independent judgement. |
| 503A compounding pharmacy | A state-licensed pharmacy compounding for an individual patient against a specific prescription. | State board of pharmacy; FDA for some provisions | Not FDA-approved. Products are not reviewed before marketing. |
| 503B outsourcing facility | An FDA-registered facility that may compound in bulk without patient-specific prescriptions. | FDA, including cGMP inspection | Still not making FDA-approved products. |
| Manufacturer | Eli Lilly, Novo Nordisk. Makes the FDA-approved branded drug. | FDA — full premarket approval | Not involved in compounded products at all. |
Equally: a provider's statement about which pharmacy it uses is a provider-reported relationship until someone verifies it. We label it that way, and so should you when you read it.
Eligibility, and who is likely to be declined
A licensed clinician decides whether treatment is appropriate. No website can promise you eligibility, and one that implies it should worry you.
Typical criteria for GLP-1 weight management follow the approved labels: a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes. Absolute contraindications include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, and pregnancy. A history of pancreatitis, gallbladder disease, severe gastrointestinal disease, or diabetic retinopathy changes the risk calculation and must be disclosed.
Be honest on the intake form. The temptation to shade an answer to secure a prescription is understandable and it is a bad trade: the questions exist because the contraindications are real.
State availability, and why it varies
Availability is not uniform across the United States, and the reasons are structural rather than arbitrary. Clinicians must be licensed in your state, not merely somewhere. Pharmacies must hold a non-resident licence to ship into your state. Some states impose additional telehealth requirements — a synchronous video visit rather than an asynchronous questionnaire, for instance — and some restrict compounded products more tightly than others.
The practical consequence is that a provider genuinely available in Texas may not serve California or North Carolina, and pricing sometimes differs by state as well. Confirm availability for your state before you compare anything else, because a cheaper provider that cannot ship to you is not cheaper.
Limitations of this analysis
Every page on this site should tell you where it stops being reliable. This one stops here.
Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.
Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.
We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.
Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.
We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and we may earn a commission from provider links. That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.
Frequently asked questions
Is microdose tirzepatide as effective as a full dose?
No. The trials that established tirzepatide's efficacy used 5-15 mg. A roughly 1 mg microdose sits below all of them and has no equivalent trial evidence. Expect a smaller effect.
Why did so many providers suddenly start offering microdosing?
The timing tracks the end of FDA enforcement discretion in early 2025 almost exactly. A dose that is not 'the same, similar, or easily substitutable' for an approved strength falls outside the 'essentially a copy' prohibition — which is the remaining route for a 503A pharmacy to compound these molecules. It is a legal mechanism at least as much as a clinical one, and no one selling it will tell you that.
Is microdosing safer?
Lower doses generally cause milder gastrointestinal effects, but they do not remove the class boxed warning or the contraindications, and the compounded product itself is not FDA-approved. Any low-dose regimen should be clinician-directed.
Sources
- U.S. Food and Drug Administration — labels and safety communications.
- Peer-reviewed clinical trials cited above.
- Our methodology and medical review policy.